PTC Therapeutics, Inc. Other Non-Current Liabilities
PTC Therapeutics, Inc. (PTCT) had Other Non-Current Liabilities of $14.50 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-07-30
- 2026-06-30: Other Liabilities, Noncurrent $14.50M.
- 2026-03-31: Other Liabilities, Noncurrent $13.70M.
- 2025-12-31: Other Liabilities, Noncurrent $13.70M.
- 2025-09-30: Other Liabilities, Noncurrent $2.58M.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $14.50M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $13.70M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $13.70M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $2.58M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $7.82M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $22.43M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $21.43M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $77.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $141.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $141.00K 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $141.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | $141.00K 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $141.00K 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $141.00K 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $2.64M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $4.69M 10-Q · filed 2022-10-27 | |
| 2021-09-30 | $1.38M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $1.39M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $1.39M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $1.39M 10-K · filed 2022-02-22 | |
| 2020-09-30 | $1.97M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $26.68M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $14.79M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $141.00K 10-K · filed 2021-02-25 | $9.16M 10-K · filed 2020-03-02 |
| 2019-09-30 | $9.46M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $8.42M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $8.77M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $58.00K 10-K · filed 2020-03-02 | |
| 2018-09-30 | $101.00K 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $153.00K 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $209.00K 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $243.00K 10-K · filed 2019-03-01 | |
| 2017-09-30 | $269.00K 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $292.00K 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $311.00K 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $335.00K 10-K · filed 2018-03-06 | |
| 2016-09-30 | $2.52M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $2.09M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $1.98M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $2.05M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $2.06M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $2.16M 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $2.29M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $2.28M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $2.24M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $2.22M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $2.26M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $2.23M 10-K · filed 2015-03-02 | $2.23M 10-K · filed 2014-03-06 |
| 2013-09-30 | $2.29M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $2.52M 10-Q · filed 2013-08-13 | |
| 2012-12-31 | $2.55M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |